Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
STAAR Surgical Company (NASDAQ: STAA) has appointed Elizabeth Yeu, M.D. and K. Peony Yu, M.D. to its Board of Directors, effective January 21, 2021. Their addition highlights the company's commitment to excellence and growth in the field of ophthalmology. Yeu is a respected ophthalmic surgeon with extensive leadership experience, while Yu has over 25 years in biomedical leadership, having served as Chief Medical Officer at FibroGen. John Moore, a board member since 2008, will retire at the 2021 Annual Shareholders Meeting. The new appointments aim to enhance STAAR's strategic goals in refractive vision correction.
STAAR Surgical Company (NASDAQ: STAA) announced preliminary fourth quarter and fiscal year results for the period ending January 1, 2021. Expected total net sales are approximately $46 million for Q4 and $163 million for the full year. GAAP earnings per share is projected to be around $0.06 for Q4 and $0.12 for the fiscal year. The company reported a rise in ICL units across various regions, with significant growth in countries like China and Japan. STAAR plans to advance commercialization of its EVO product initiatives and maintain a growth target of 25% compound annual revenue increase over three years.
STAAR Surgical Company (NASDAQ: STAA) has announced the successful initial commercialization of its EVO Viva™ lens, specifically targeting presbyopia patients. The first implantation occurred on October 23 in Belgium and received positive feedback. This lens aims to provide visual freedom for individuals aged 40-50 struggling with near vision. Consumer websites in multiple languages are active, and clinical data supporting the lens's efficacy has been published. The company plans to collaborate with surgeons to optimize the product’s integration in clinical practice.
STAAR Surgical Company (NASDAQ: STAA) reported a strong performance for Q3 2020, achieving record net sales of $47.1 million, up 21% year-over-year. Key drivers include ICL sales of $41.5 million, representing a 23% increase, and a 25% rise in ICL units sold. Gross margin was 74.1%, slightly lower than 74.4% in Q3 2019. Net income rose to $3.9 million or $0.08 per share from $2.4 million or $0.05 per share in the prior year. Cash reserves increased to $128.3 million. Despite strong growth, markets in India and the Middle East were adversely affected by COVID-19.
STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the third quarter ended October 2, 2020, on November 4, 2020, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Interested parties can access the call at 833-350-1429 (domestic) or 647-689-6661 (international). A replay and archived webcast will be available shortly after the call. STAAR specializes in implantable lenses and has marketed over 1,000,000 Visian® ICLs worldwide.